# CJC-1295 Ipamorelin: The Research on This GHRH + GHRP Stack

> CJC-1295 ipamorelin is a GHRH + GHRP combination studied for supra-additive GH secretion. This page covers the mechanistic rationale, ipamorelin selectivity data, GHRP-2 comparison, and MK-677 mechanistic differences.

## Mechanistic Rationale for the CJC-1295 + Ipamorelin Stack

The mechanistic rationale for combining CJC-1295 and ipamorelin rests on two distinct pituitary secretagogue pathways.

CJC-1295 amplifies GH release via GHRH receptor (GHRH-R) agonism — a Gαs/cAMP/PKA cascade that drives both GH exocytosis and GH gene transcription [12]. Ipamorelin stimulates GH release via a distinct ghrelin receptor pathway (GHS-R1a) using calcium-dependent intracellular signaling [5]. Because the two receptors are independent, their downstream GH-release signals are additive at the pituitary level.

The synergy of GHRH + GHRP-class peptides has been demonstrated in human volunteers: combining GHRP-2 with GHRH pulses produced significantly greater pulsatile GH output than either alone — interactive effect P<0.01 [7]. The CJC-1295 + ipamorelin combination has not been studied in a dedicated peer-reviewed human clinical trial; the synergy rationale is extrapolated from the GHRH + GHRP class literature.

Ipamorelin was the first GHRP reported to stimulate GH release without producing significant ACTH, cortisol, or prolactin elevation, even at doses 200× above its GH ED50 [5].

## Research Applications of the CJC-1295 / Ipamorelin Stack

Preclinical research models test the combination for enhanced GH secretion synergy, lean body mass support, bone density [10], and recovery from musculoskeletal injury [11]. The GHRH-class analog tesamorelin reduced visceral adipose tissue by ~18% at twelve months in human RCTs [9].

In rat models, ipamorelin counteracted glucocorticoid-induced bone loss — periosteal bone formation rate was four times higher in the ipamorelin group at 100 μg/kg SC three times daily for three months [10]. Ipamorelin also counteracted prednisolone-induced catabolism, improving nitrogen balance comparably to exogenous GH [11].

## CJC-1295 + Ipamorelin: Research Protocols

In published and observational research protocols, the two peptides are typically co-administered by subcutaneous injection. Ipamorelin terminal half-life: approximately 2 hours; peak GH response at approximately 0.67 hours post-injection [6]. CJC-1295 with DAC half-life: 5.8–8.1 days [1]. The CJC-1295 with-DAC form provides tonic background GH elevation while each ipamorelin injection adds a discrete GH pulse on top.

## Lean Mass and Fat Oxidation Outcomes in Research

Preclinical rodent models demonstrate lean mass preservation and fat mass reduction with combined GHRH + GHRP administration. The GHRH analog class in human RCTs (tesamorelin) produced significant visceral adipose tissue reduction [9]; a 2026 meta-analysis confirmed the class effect [21]. Body-composition effect data for CJC-1295 specifically is not established in human trials.

## CJC-1295 + Ipamorelin vs GHRP-2: Selectivity Differences

GHRP-2 produces larger GH pulses when combined with GHRH analogs [7], but also elevates ACTH and cortisol via non-selective GHS-R binding. Ipamorelin is highly selective for GHS-R1a — no ACTH or cortisol elevation at doses 200× the GH ED50 [5]. Selectivity is the key documented difference.

## CJC-1295 / Ipamorelin vs MK-677: Mechanistic Comparison

MK-677 (ibutamoren) is orally active and produces sustained 24-hour GH elevation. CJC-1295 + ipamorelin is injectable and produces pulsatile GH. No direct comparative human clinical trial exists; the comparison is mechanistic only [20].

## What Are the Downsides of CJC-1295 Ipamorelin?

The stacked combination amplifies GH pulse magnitude. Documented downsides include more pronounced water retention and flushing than either peptide alone [13], consistent with higher GH-driven distal nephron sodium reabsorption [8]. No published human RCT has characterized adverse events specifically for the combined regimen.

## References

[1] Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[3] Jetté L, et al. Endocrinology. 2005;146(7):3052-8. https://pubmed.ncbi.nlm.nih.gov/15817669/
[5] Raun K, et al. Eur J Endocrinol. 1998;139(5):552-61. https://pubmed.ncbi.nlm.nih.gov/9849822/
[6] Gobburu JV, et al. Pharm Res. 1999;16(9):1412-6. https://pubmed.ncbi.nlm.nih.gov/10496658/
[7] Norman C, et al. Am J Physiol Regul Integr Comp Physiol. 2013;305(4):R378-86. https://pubmed.ncbi.nlm.nih.gov/23485864/
[8] Johannsson G, et al. J Clin Endocrinol Metab. 2002;87(4):1743-9. https://pubmed.ncbi.nlm.nih.gov/11932310/
[9] Falutz J, et al. J Acquir Immune Defic Syndr. 2010;53(3):311-22. https://pubmed.ncbi.nlm.nih.gov/20101189/
[10] Andersen NB, et al. Growth Horm IGF Res. 2001;11(5):266-72. https://pubmed.ncbi.nlm.nih.gov/11735244/
[11] Aagaard NK, et al. Growth Horm IGF Res. 2009;19(5):426-31. https://pubmed.ncbi.nlm.nih.gov/19231263/
[12] Halmos G, et al. Rev Endocr Metab Disord. 2025. https://pubmed.ncbi.nlm.nih.gov/39934495/
[13] Teichman SL, et al. [Adverse events.] J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[20] Ionescu M, Frohman LA. [MK-677 context.] J Clin Endocrinol Metab. 2006;91(12):4792-7. https://pubmed.ncbi.nlm.nih.gov/17018654/
[21] Various authors. Body composition outcomes of Tesamorelin. ScienceDirect (in press 2026). https://pubmed.ncbi.nlm.nih.gov/41545261/

---

A letterpress monograph on the GHRH analog CJC-1295 — with-DAC and without, hand-set from the peer-reviewed record, no clinic, no counter.